Hélène Dulude

1.0k total citations
37 papers, 798 citations indexed

About

Hélène Dulude is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Hélène Dulude has authored 37 papers receiving a total of 798 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 9 papers in Cancer Research. Recurrent topics in Hélène Dulude's work include Prostate Cancer Treatment and Research (7 papers), Diabetes Management and Research (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Hélène Dulude is often cited by papers focused on Prostate Cancer Treatment and Research (7 papers), Diabetes Management and Research (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Hélène Dulude collaborates with scholars based in Canada, United States and United Kingdom. Hélène Dulude's co-authors include Claude A. Piché, Luc Daigneault, Chandra J. Panchal, G. Gallant, Jonathan R. Reeves, Cristina B. Guzmán, Shuyu Zhang, Emmanouil Rampakakis, Dharam Ramnani and Brandon M. Nathan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Diabetes Care.

In The Last Decade

Hélène Dulude

36 papers receiving 742 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hélène Dulude Canada	16	326	193	184	160	160	37	798
A. Eisenhardt Germany	16	141 0.4×	139 0.7×	97 0.5×	163 1.0×	67 0.4×	48	729
Thomas Strack United States	13	451 1.4×	63 0.3×	125 0.7×	257 1.6×	178 1.1×	56	760
J. Verhelst Belgium	16	969 3.0×	110 0.6×	179 1.0×	448 2.8×	73 0.5×	41	1.3k
Steve White United Kingdom	16	203 0.6×	285 1.5×	159 0.9×	651 4.1×	109 0.7×	48	1.3k
Philip A. DeSimone United States	7	185 0.6×	161 0.8×	71 0.4×	109 0.7×	88 0.6×	16	618
Yuh‐Seog Jung South Korea	15	224 0.7×	170 0.9×	63 0.3×	225 1.4×	66 0.4×	48	696
A.T.A. Fazekas Canada	18	570 1.7×	93 0.5×	609 3.3×	81 0.5×	217 1.4×	36	1.4k
Tony T. Wu Taiwan	15	135 0.4×	327 1.7×	542 2.9×	156 1.0×	91 0.6×	32	1.1k
Joëlle Blumberg France	16	417 1.3×	1.5k 7.6×	146 0.8×	232 1.4×	108 0.7×	28	2.3k
G. Bartsch Austria	16	135 0.4×	69 0.4×	376 2.0×	97 0.6×	100 0.6×	50	638

Countries citing papers authored by Hélène Dulude

Since Specialization

Citations

This map shows the geographic impact of Hélène Dulude's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hélène Dulude with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hélène Dulude more than expected).

Fields of papers citing papers by Hélène Dulude

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hélène Dulude. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hélène Dulude. The network helps show where Hélène Dulude may publish in the future.

Co-authorship network of co-authors of Hélène Dulude

This figure shows the co-authorship network connecting the top 25 collaborators of Hélène Dulude. A scholar is included among the top collaborators of Hélène Dulude based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hélène Dulude. Hélène Dulude is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Seaquist, Elizabeth R., Hélène Dulude, Rémi Rabasa‐Lhoret, et al.. (2018). Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real‐world setting. Diabetes Obesity and Metabolism. 20(5). 1316–1320. 41 indexed citations

Yale, Jean‐François, et al.. (2017). Faster Use and Fewer Failures with Needle-Free Nasal Glucagon Versus Injectable Glucagon in Severe Hypoglycemia Rescue: A Simulation Study. Diabetes Technology & Therapeutics. 19(7). 423–432. 70 indexed citations

Guzmán, Cristina B., Hélène Dulude, Claude A. Piché, et al.. (2017). Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial. Diabetes Obesity and Metabolism. 20(3). 646–653. 23 indexed citations

Annabi, Borhane, Jean-Christophe Currie, Hélène Dulude, et al.. (2006). Contribution of the 37-kDa laminin receptor precursor in the anti-metastatic PSP94-derived peptide PCK3145 cell surface binding. Biochemical and Biophysical Research Communications. 346(1). 358–366. 13 indexed citations

Annabi, Borhane, Jean-Christophe Currie, Hélène Dulude, et al.. (2006). Inhibition of MMP-9 secretion by the anti-metastatic PSP94-derived peptide PCK3145 requires cell surface laminin receptor signaling. Anti-Cancer Drugs. 17(4). 429–438. 15 indexed citations

Reeves, Jonathan R., Hélène Dulude, Chandra J. Panchal, Luc Daigneault, & Dharam Ramnani. (2006). Prognostic Value of Prostate Secretory Protein of 94 Amino Acids and its Binding Protein after Radical Prostatectomy. Clinical Cancer Research. 12(20). 6018–6022. 60 indexed citations

Hawkins, Robert E., Luc Daigneault, Richard Cowan, et al.. (2005). Safety and Tolerability of PCK3145, a Synthetic Peptide Derived from Prostate Secretory Protein 94 (PSP94) in Metastatic Hormone-Refractory Prostate Cancer. PubMed. 4(2). 91–99. 12 indexed citations

Annabi, Borhane, Jean-Christophe Currie, Robert D. Hawkins, et al.. (2005). A PSP94-derived Peptide PCK3145 inhibits MMP-9 Secretion and Triggers CD44 Cell Surface Shedding: Implication in Tumor Metastasis. Clinical & Experimental Metastasis. 22(5). 429–439. 33 indexed citations

Hawkins, Robert D., C. Panchal, Hélène Dulude, et al.. (2004). A multiple ascending dose, open-label, phase IIa study evaluating the safety and tolerability of PCK3145 administered intravenously in patients with metastatic hormone refractory prostate cancer (HRPC). Journal of Clinical Oncology. 22(14_suppl). 4636–4636. 2 indexed citations

10.

Trudeau, Marc, Gavin Stuart, Hal W. Hirte, et al.. (2002). A Phase II Trial of JM-216 in Cervical Cancer: An NCIC CTG Study. Gynecologic Oncology. 84(2). 327–331. 21 indexed citations

11.

Trudeau, Maureen, R. J. Seymour, G. Stanimir, et al.. (2000). A phase II trial of mitomycin, ifosfamide and cisplatin in recurrent carcinoma of the cervix. International Journal of Gynecological Cancer. 10(3). 207–211. 4 indexed citations

12.

Goss, Paul E., A. Keith Stewart, Félix Couture, et al.. (1999). Combined Results of Two Phase Il Studies of Taxol (Paclitaxel) in Patients with Relapsed or Refractory Lymphomas. Leukemia & lymphoma. 34(3-4). 295–304. 13 indexed citations

13.

Bjarnason, Georg A., C. Cripps, Rakesh Goel, et al.. (1998). Phase I-II Study of 5-Fluorouracil, Leucovorin, Doxorubicin, Methotrexate, and Long-Term Oral Etoposide (FLAME) in Unresectable or Metastatic Gastric Cancer. American Journal of Clinical Oncology. 21(6). 537–542.

14.

Gelmon, Karen A., Anthony W. Tolcher, Séamus O’Reilly, et al.. (1998). A phase I–II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer. Annals of Oncology. 9(11). 1247–1249. 9 indexed citations

15.

Glück, Stefan, Colin Germond, Pedro López, et al.. (1998). A phase I trial of high-dose paclitaxel, cyclophosphamide and mitoxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer. European Journal of Cancer. 34(7). 1008–1014. 19 indexed citations

16.

Warner, Ellen, Rajesh Kumar Goel, Warren Chow, et al.. (1998). A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS). British Journal of Cancer. 77(12). 2376–2380. 26 indexed citations

17.

Evans, William K., Craig C. Earle, David J. Stewart, et al.. (1997). Phase II study of a one hour paclitaxel infusion in combination with carboplatin for advanced non-small cell lung cancer. Lung Cancer. 18(1). 83–94. 12 indexed citations

18.

Kirkbride, Peter, Karen Gelmon, Elizabeth A. Eisenhauer, B. Fisher, & Hélène Dulude. (1997). A phase I/II study of paclitaxel (Taxol®) and concurrent radiotherapy in advanced nonsmall cell lung cancer. International Journal of Radiation Oncology*Biology*Physics. 39(5). 1107–1111. 17 indexed citations

19.

Gallant, G., et al.. (1995). Synthesis and preliminary in vitro cytotoxicity evaluation of 1,3-bis-(2-propynyl)-1-nitrosourea (BPNU) and derivatives.. PubMed. 14(6B). 2695–9. 2 indexed citations

20.

Dulude, Hélène, et al.. (1995). Synthesis and anti-HIV activity of new urea and nitrosourea derivatives of diamino acids. Bioorganic & Medicinal Chemistry. 3(2). 151–160. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact